Keyphrases
Protease Inhibitors
100%
Viral Escape
100%
Hepatitis C Virus Genotypes
100%
Inhibitor Activity
100%
Genotype 1
45%
Hepatitis C Virus
36%
Recombinant
27%
Clinically Significant
27%
Genotype
18%
Short-term Treatment
18%
Co-selection
18%
Next-generation Sequencing
18%
Genotype 3
18%
Long-term Treatment
18%
Protease
18%
Fitness Cost
18%
Hepatitis C Virus Inhibitors
9%
Pan-genome
9%
Additional Resistance
9%
Cell Culture
9%
Viral Spread
9%
EC50
9%
Huh7.5
9%
Median Effective Concentration
9%
Minor Effect
9%
Linkage Analysis
9%
Virus Escape
9%
Resistance Test
9%
Resistance-associated Substitutions
9%
Resistance to Change
9%
Haplotype Analysis
9%
Protease Inhibitor Resistance
9%
Concentration-dependent
9%
Evolution Mechanism
9%
Amino Acid Variation
9%
Infectious Hepatitis
9%
Polymorphism
9%
Virus
9%
Virus Isolate
9%
Cells in Culture
9%
Chronic Hepatitis C Virus Infection
9%
Lay Summary
9%
Biochemistry, Genetics and Molecular Biology
Hepatitis C Virus Genotype 1
100%
Protease Inhibitor
100%
Genotyping
53%
Simeprevir
46%
Hepatitis C Virus
46%
Protease
38%
Next Generation Sequencing
15%
EC50
15%
Recombinant
15%
Evolution
7%
Hepatitis C Virus Subtype 1a
7%
Haplotype
7%
Gene Linkage
7%
Cell Culture
7%
Amino Acid
7%
Immunology and Microbiology
Simeprevir
100%
Hepatitis C Virus Genotype 1
100%
Hepatitis C Virus
83%
EC50
33%
Next Generation Sequencing
33%
Cell Culture
16%
Haplotype
16%
Amino Acid
16%
Virus
16%
Hepatitis C Virus Subtype 1a
16%
Evolution
16%
Hepatitis C
16%
Pharmacology, Toxicology and Pharmaceutical Science
Voxilaprevir
53%
Glecaprevir
53%
Infectious Hepatitis
7%